InterMune

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, InterMune sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 7 completed top decile by trial count

InterMune: 11 sponsored US clinical trials, none currently recruiting.

InterMune sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteopetrosis, with 1 trials.

Top-decile sponsor footprint

InterMune ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

7 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 2

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

NCT00084279
TERMINATED Phase 3

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)

NCT00075998
TERMINATED Phase 3

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

NCT00076635
TERMINATED Phase 1

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

NCT00057447
COMPLETED Phase 2

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00052052
COMPLETED

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

NCT00043329
COMPLETED Phase 2

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047658
TERMINATED Phase 3

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

NCT00047632
COMPLETED Phase 1

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

NCT00043316
COMPLETED Phase 3

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047645
COMPLETED Phase 2

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00012467

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 4

Therapeutic Areas

Osteopetrosis 1
Cystic Fibrosis 1

How the InterMune archive is shaped

11 indexed studies, none listed as recruiting (0% open); 7 completed (64%).

Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).

Top condition: Osteopetrosis (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

InterMune: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

InterMune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share InterMuneAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
InterMune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

InterMune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this InterMune page

11 registered trials is a research-attention snapshot, not an endorsement of InterMune or any single study.

  • None of InterMune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Osteopetrosis is the condition InterMune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteopetrosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

InterMune pipeline card: 11 registered trials from official public datasets.Report a data error.